RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment (RAISE)

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Study Overview

• Status: Recruiting
• Conditions: Migraine; Chronic Migraine; Migraine Without Aura; Migraine With Aura
• Intervention / Treatment: Drug: Rimegepant 75 mg

Detailed Description

Rimegepant belongs to the gepants family, small molecules calcitonin gene- related peptide (CGRP) receptor antagonists. It is a new generation gepant, currently available as an orally disintegrating tablet at a single dose of 75 mg.

It has a double indication both for acute treatment for migraine with and without aura and preventive treatment of migraine. A previous randomized, placebo-controlled phase 2/3 trial demonstrated its effectiveness and tolerability in the preventive setting for patients with episodic and chronic migraine. Previous studies also demonstrated a good tolerability profile. The most commonly reported adverse events were nausea, nasopharyngitis, upper respiratory tract infections and urinary tract infections.

In this prospective multicentric study the investigators aim to evaluate rimegepant effectiveness and tolerability as preventive migraine treatment in a real-world setting. Subjects who meet the inclusion criteria will be enrolled and will participate in the study. Baseline demographic and clinical data will be collected at the baseline visit. The observation period will last for two years during which patients will take rimegepant 75 mg orally disintegrating tablet every other day for a time period related to eventual approval of reimbursability criteria.

Data will be collected at baseline and every three months for two years. Subjects will be asked to keep a headache diary to collect monthly headache and migraine days, migraine severity, associated symptoms and drug consumption. Questionnaires will be collected every three months.

Data collection will focus on: i) demographic data, ii) migraine history, iii) pain intensity, iv) presence and evolution of migraine associated symptoms and aura, v) migraine associated disability, vi) tolerability and eventual treatment- emergent adverse events, vii) treatment persistence, viii) questionnaires related to disability, allodynia, quality of life, interictal burden and effectiveness of the ongoing acute and preventive treatments. The online database REDCap will be used for data collection.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Roberto De Icco, MD; Email: roberto.deicco@mondino.it
• Study Contact Backup: Name: Luigi F Iannone, MD; Phone Number: +393896969606; Email: luigifrancesco.iannone@unimore.it

Study Locations

• Italy
  • Florence, Italy, 50134
    • Recruiting
    • SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
    • Contact: Luigi F Iannone, MD; Email: luigifrancesco.iannone@unifi.it
  • Pavia, Italy, 27100
    • Recruiting
    • IRCCS National Neurological Institute "C. Mondino" Foundation
    • Contact: Roberto De Icco, MD; Email: roberto.deicco@mondino.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Multicentric study on patients attending the outpatient clinic of Italian Headache centres who meet criteria for rimegepant use for migraine preventive treatment.

Description

Inclusion Criteria:

• Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
• At least 4 monthly migraine days;
• Good compliance to study procedures;
• Availability of headache diary at least of the preceding months before enrollment.

Exclusion Criteria:

• Subjects with contraindications for use of gepants;
• Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
• medical comorbidities that could interfere with study results;
• Pregnancy and breastfeeding.
• Changes in preventive treatments in the month before the first administration of rimegepant

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Episodic migraine; Patients affected by an episodic pattern migraine(< 15 monthly headache days) with or without aura according to ICHD-III criteria.	Drug: Rimegepant 75 mg; Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention; Other Names: Rimegepant
Chronic migraine; Patients affected by chronic migraine (> 15 monthly headache days with at least 8 days with migraine features) according to ICHD-III criteria.	Drug: Rimegepant 75 mg; Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention; Other Names: Rimegepant

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in migraine frequency after three months of treatment	Changes in monthly migraine days after three months of treatment with rimegepant compared to baseline (continuous variable)	Baseline (T0) - 3 months of treatment with rimegepant (T3)
Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant	Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with rimegepant	Baseline (T0) - 3 months of treatment with rimegepant (T3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in migraine frequency across twelve months of rimegepant treatment	Change of monthly migraine days after six and twelve months of treatment with rimegepant compared to baseline (continuous variable)	Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) across twelve months of treatment with rimegepant	Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after six and twelve months of treatment with rimegepant	Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Evaluation of any adverse event (qualitative)	Type of any adverse events in patients receiving rimegepant during the observation period (categorical variable)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Evaluation of any adverse event (quantitative)	Percentage of reported adverse events in patients receiving rimegepant during the observation period (continuous variable)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Evaluation of serious adverse event	Percentage of serious adverse events (namely those resulting in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect) in patients receiving rimegepant during the observation period (continuous variable)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Evaluation of adverse event leading to treatment discontinuation	Percentage of adverse events leading to treatment discontinuation in patients receiving rimegepant during the observation period (continuous variable)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Consistency of treatment response	Percentage of patients with a stable 50% response during rimegepant treatment ( from 3 to 12 months of treatment) (continuous variable)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in migraine disability (MIDAS)	Changes in MIgraine Disability ASsement questionnaire across rimegepant treatment (continuous variable, 0-270 scale, higher scores indicate higher disability: 0-5, little/no disability; 6-10, mild disability; 11-20, moderate disability; >20, severe disability)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in migraine disability (HIT-6)	Changes in Headache Impact Test-6 questionnaire across rimegepant treatment (continuous variable, 36-78 scale, higher scores indicates greater disability)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in response to acute migraine treatment (m-TOQ)	Changes in migraine Treatment Optimization Questionnaire across rimegepant treatment (continuous variable, 0-8 scale, higher score indicates higher acute therapy effectiveness)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in allodynia across rimegepant treatment (ASC-12)	Changes in Allodynia Symptoms Checklist-12 questionnaire across rimegepant treatment (continuous variable, 0-24 scale, higher score indicates more severe allodynia)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in quality of life across rimegepant treatment (MSQ)	Changes in Migraine Specific Quality of life questionnaire across rimegepant treatment (continuous variable, 0-100 scale, 100 indicates full functionality)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in interictal burden across rimegepant treatment (MIBS-4)	Changes in Migraine Interictal Burden Scale-4 questionnaire across rimegepant treatment (continuous variable, 0-4 scale, 0 indicates no interictal burden, 1-2 mild level of interictal burden, 3 moderate interictal burden, 4 severe interictal burden)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Percentage of patients with Medication overuse headache reverted during treatment	Percentage of patients with a baseline diagnosis of MOH reverted after 3 - 6 and 12 months of rimegepant treatment (continuous variable)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in the number of monthly migraine days with aura (quantitative)	Changes in the number of monthly migraine days with aura across rimegepant treatment (continuous variable, through headache diary assessment)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Variation of duration of aura (qualitative)	Changes in duration of aura across rimegepant treatment (categorical variable - minutes, assessed through headache diary)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Variation of type of aura (qualitative)	Changes in type of aura across rimegepant treatment (assessed through headache diary and anamnestic data collection)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
MMDs reduction in patients Non-responders to mAbs	Change of monthly migraine days across rimegepant treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Percentage of 50% Responders in patients Non-responders to anti CGRP mAbs	Percentage of 50% Responders across rimegepant treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Menstrually-related migraine	Change in the number of menstrually-related attacks (according to ICHD-3) across rimegepant treatment compared to baseline (continuous variable)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Change in self-reported effectiveness of rimegepant treatment	Change in Patients Global Impression of Change (PGIC) questionnaire across treatment (continuous variable, scale 0-7, 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse)	3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in migraine severity	Changes in migraine severity (continuous variable, 0-10 numerical rating scale, higher scores indicate higher severity)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in migraine duration across treatment	Changes in migraine duration across treatment (continuous variable, hours, assessed through a paper diary)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in duration of the most bothersome symptom(s)	Changes in duration of the most bothersome symptom(s) (continuous variable, minutes, assessed through a paper diary)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in severity of the most bothersome symptom(s)	Changes in severity of the most bothersome symptom(s) (continuous variable: 0-10 numerical rating scale, higher scores indicate higher severity)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant
Changes in self-reported effectiveness of acute treatment	Changes in self-reported effectiveness of usual acute treatment (Patients Global Impression of Change questionnaire across treatment: continuous variable, scale 0-7, 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse)	Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with rimegepant

Collaborators and Investigators

• Sponsor: University of Florence
• Collaborators: University of Roma La Sapienza; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; IRCCS National Neurological Institute "C. Mondino" Foundation; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; Azienda Policlinico Umberto I; Cliniche Humanitas Gavazzeni; Ospedale Santo Stefano; Azienda Ospedaliero Universitaria Policlinico Modena; Ospedale di Piove di Sacco; A.O.U. Città della Salute e della Scienza; Asst Degli Spedali Civili Di Brescia; University of Campania Luigi Vanvitelli; Società Italiana per lo Studio delle Cefalee; Auxologico San Luca

Publications and helpful links

General Publications

• Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
• Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15.

Study record dates

Study Major Dates

• Study Start (Actual): March 26, 2024
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): September 1, 2027

Study Registration Dates

• First Submitted: April 5, 2024
• First Submitted That Met QC Criteria: May 7, 2024
• First Posted (Actual): May 10, 2024

Study Record Updates

• Last Update Posted (Actual): January 21, 2026
• Last Update Submitted That Met QC Criteria: January 19, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Pain; Headache; Medication overuse headache; Migraine prevention; Rimegepant; Gepant
• Additional Relevant MeSH Terms: Neurologic Manifestations; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Headache Disorders, Primary; Headache Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Pain; Migraine Disorders; Headache; Migraine with Aura; Migraine without Aura; Headache Disorders, Secondary; rimegepant sulfate
• Other Study ID Numbers: RICe_3

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No